✦ New CED Clinical Relevance #78Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News | CED Clinic ResearchClinical EvidenceAcademic MedicineDrug DevelopmentCannabis Science Why This MattersAcademic partnerships between Yale and McGill represent...
ARTELO BIOSCIENCES, INC. SEC 10-K Report – TradingView
WHY IT MATTERS: If endocannabinoid-targeted pharmaceuticals like these gain FDA approval, patients dealing with cancer-related weight loss and chemotherapy nerve pain could eventually have insurance-covered, standardized treatment options that work through the same system cannabis does. CLINICAL OVERVIEW: Artelo Biosciences is advancing pharmaceutical candidates that target the endocannabinoid system, including ART27.13 for cancer-related anorexia and ART26.12 for chemotherapy-induced peripheral neuropathy. These drug development programs represent a growing trend of biotech companies working to create FDA-approvable medications that modulate endocannabinoid pathways rather than relying solely on plant-derived cannabinoids.
The endocannabinoid system mediates the enhanced analgesia and GI safety advantage of a newly developed NSAID derivative
Enhanced Analgesic Effects and GI Safety of A Novel Hydrogen Sulfide‐Releasing Anti‐Inflammatory Drug (ATB‐352): A Role for Endogenous Cannabinoids In Summary Nonsteroidal anti‐inflammatory drugs (NSAIDs) are the preferable alternatives to opioids in...